164 related articles for article (PubMed ID: 29602380)
21. [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].
Bellocq JP; Luporsi E; Barrière J; Bonastre J; Chetritt J; Le Corroller AG; de Crémoux P; Fina F; Gauchez AS; Kassab-Chahmi D; Lamy PJ; Martin PM; Mazouni C; Peyrat JP; Romieu G; Verdoni L; Mazeau-Woynar V
Ann Pathol; 2014 Oct; 34(5):349-51. PubMed ID: 25439987
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
Xian Z; Quinones AK; Tozbikian G; Zynger DL
Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
[TBL] [Abstract][Full Text] [Related]
23. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
[TBL] [Abstract][Full Text] [Related]
24. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
25. Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
Trigo J; García-Cosío M; García-Castaño A; Gomà M; Mesia-Nin R; Ruiz-Bravo E; Soria-Rivas A; Castillo P; Braña-García I; Alberola-Ferranti M
Clin Transl Oncol; 2022 Oct; 24(10):1890-1902. PubMed ID: 35739348
[TBL] [Abstract][Full Text] [Related]
26. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Vera R; Ibarrola-de-Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B
Clin Transl Oncol; 2022 Nov; 24(11):2107-2119. PubMed ID: 36008616
[TBL] [Abstract][Full Text] [Related]
27. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer.
Criscitiello C; Bagnardi V; Pruneri G; Vingiani A; Esposito A; Rotmensz N; Curigliano G
Eur J Cancer; 2017 Dec; 87():164-171. PubMed ID: 29154173
[TBL] [Abstract][Full Text] [Related]
29. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
García-Alfonso P; García-Foncillas J; Salazar R; Pérez-Segura P; García-Carbonero R; Musulén-Palet E; Cuatrecasas M; Landolfi S; Ramón Y Cajal S; Navarro S; ;
Clin Transl Oncol; 2015 Apr; 17(4):264-73. PubMed ID: 25373533
[TBL] [Abstract][Full Text] [Related]
30. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
31. Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Remon J; García-Campelo R; de Álava E; Vera R; Rodríguez-Peralto JL; Rodríguez-Lescure Á; Bellosillo B; Garrido P; Rojo F; Álvarez-Alegret R
Clin Transl Oncol; 2020 Jun; 22(6):823-834. PubMed ID: 31559582
[TBL] [Abstract][Full Text] [Related]
32. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.
Dobbe E; Gurney K; Kiekow S; Lafferty JS; Kolesar JM
Am J Health Syst Pharm; 2008 Jan; 65(1):23-8. PubMed ID: 18159035
[TBL] [Abstract][Full Text] [Related]
33. The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy.
Venetis K; Pescia C; Cursano G; Frascarelli C; Mane E; De Camilli E; Munzone E; Dellapasqua S; Criscitiello C; Curigliano G; Guerini Rocco E; Fusco N
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891906
[TBL] [Abstract][Full Text] [Related]
34. [2018 Consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary].
Matías-Guiu X; Fusté V; Iglesias L; Balañá C; Concha Á; de la Cruz-Merino L; Nieto B; Pané M; Sanz J; Losa F
Rev Esp Patol; 2019; 52(1):33-44. PubMed ID: 30583830
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
36. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
37. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
[TBL] [Abstract][Full Text] [Related]
38. Oncotype DX
Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
[TBL] [Abstract][Full Text] [Related]
39. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
40. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
